GSK: New Data Shows RSV Vaccine's Potential In Adults Aged 50 To 59 At Increased Risk For RSV-LRTD

(RTTNews) - GSK plc (GSK, GSK.L) reported positive preliminary results from phase III trial evaluating the immune response and safety of Arexvy in adults aged 50 to 59, including those at increased risk of respiratory syncytial virus lower respiratory tract disease due to certain underlying medical conditions. The company said the vaccine elicited an immune response that was non-inferior to that observed in adults aged 60 and above, meeting the trial's primary co-endpoint. The co-primary endpoint was also met for the broader group of adults aged 50 to 59 enrolled in the trial. Safety and reactogenicity data were consistent with results from the initial phase III programme.

Tony Wood, Chief Scientific Officer, GSK, said: "We will submit these data for regulatory review as quickly as possible with the goal of offering adults in this age group the option of a vaccine for the first time."

The vaccine is currently approved in the US for active immunisation for the prevention of RSV-LRTD in adults 60 years of age and older. It is approved in Europe, Japan and several other countries.

For More Such Health News, visit rttnews.com.